Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.57 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413359 | 0.88 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1MAPT | |
| SCHEMBL4251502 | 0.86 | BRAF (0.61) | MAPTNPSR1HTTMEN1KMT2A | |
| SCHEMBL2679303 | 0.86 | MAPT (0.55) | MAPTNPSR1HTTMEN1KMT2A | |
| SCHEMBL3302139 | 0.85 | KCNQ3 (0.55) | KCNQ3KCNQ2KCNE1KCNQ1MAPT | |
| SCHEMBL3300398 | 0.84 | MAPT (0.54) | MAPTNPSR1HTTMEN1KMT2A | |
| SCHEMBL12518236 | 0.84 | KIT (0.51) | MAPTNPSR1HTTMEN1KMT2A | |
| SCHEMBL22025295 | 0.83 | PTGS1 (0.64) | MAPTNPSR1MEN1KMT2ANPC1 | |
| SCHEMBL5498213 | 0.82 | KIT (0.61) | KCNQ3KCNQ2KCNE1KCNQ1MAPT | |
| SCHEMBL19070454 | 0.82 | MAPT (0.59) | KCNQ3KCNQ2MAPTMEN1KMT2A | |
| SCHEMBL19500724 | 0.82 | KIT (0.58) | KCNQ3KCNQ2KCNE1KCNQ1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | HOLZER PHILIPP | 2010-04-15 | — | — | US | claimed |
| EP-2079745-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| EP-2079702-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008052974-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | claimed |
| WO-2008052964-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | claimed |
| EP-1918291-A1 | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | HOLZER PHILIPP | 2010-04-15 | — | — | US | disclosed |
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | IMBACH PATRICIA | 2010-03-18 | — | — | US | disclosed |
| EP-2079702-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-2079745-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| CN-101351467-A | 3- (substituted amino) -pyrazolo [3, 4-d ] pyrimidines as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2009-01-21 | — | — | CN | disclosed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008052974-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008052964-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918291-A1 | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | PRKCA, PRKACA, MAP3K19 | KCNQ3 2427/4885KCNQ2 2396/4885KCNE1 2010/4885 |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | KCNQ3 2226/4885KCNQ2 2585/4885KCNE1 2352/4885 |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | MAP4K2, MAP4K3, MAP4K1 | KCNQ3 1140/4885KCNQ2 1229/4885KCNE1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.